[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356442-105":3,"doc-detail-356442-en":81,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-humanized-lif-targeting-antibody-synergistically-enhances-chemoand-immunotherapy-in-pancreatic-cancer","A humanized LIF-targeting antibody synergistically enhances chemoand immunotherapy in pancreatic cancer","","Pancreatic cancer is linked to poor survival driven by late diagnosis and resistance to chemotherapy and immunotherapy. Leukemia inhibitory factor (LIF), an IL-6 family cytokine, promotes pancreatic cancer progression and is explored as a therapeutic target. The study validates LIF druggability and develops an antibody-mediated LIF blockade strategy to potentiate gemcitabine-based chemotherapy and PD-1-targeted immunotherapy for pancreatic ductal adenocarcinoma.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-humanized-lif-targeting-antibody-synergistically-enhances-chemoand-immunotherapy-in-pancreatic-cancer/356442/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-humanized-lif-targeting-antibody-synergistically-enhances-chemoand-immunotherapy-in-pancreatic-cancer/356442.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapeutic target does the study focus on in pancreatic ductal adenocarcinoma?","Question",{"text":63,"@type":64},"The study focuses on leukemia inhibitory factor (LIF) and aims to validate LIF as a therapeutic target using antibody-mediated LIF blockade.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the humanized anti-LIF antibody generated and evaluated?",{"text":68,"@type":64},"A humanized anti-LIF antibody was created using a murine framework with structural optimization of VL/VH domains to reduce immunogenicity. Binding affinity was measured using surface plasmon resonance (SPR), and antitumor efficacy was tested in multiple preclinical models.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes did the study report for combining the antibody with standard treatments?",{"text":72,"@type":64},"Selective targeting of LIF enhanced chemosensitivity to gemcitabine and improved the efficacy of PD-1-targeted immunotherapy, with the humanized antibody showing higher specificity, affinity, and tumor growth inhibition than the murine version.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356442,1790187101,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":33,"preview_urls":98},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Xu etal. Journal of Translational Medicine (2026) 24:318  \n[https://doi.org/10.1186/s12967-026-07723-z](https://doi.org/10.1186/s12967-026-07723-z)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nA humanized LIF-targeting antibody synergistically enhances chemoand immunotherapy in pancreatic cancer  \nFu Xu1, Wei Liu1, Luying Su1, Lang Yang2, Yiyao Zhang1, Baoqing Liu1, Shuaihu Liu1, Zuoming Liu 1, Ziran Chen1, Yan Lu1, Ning Zhang4, Rong Huang1*, Hong Zhao2,3* and Wei Song1*  \nAbstract  \nBackground Pancreatic cancer is associated with a low survival rate due to its late diagnosis, and the patients’resistance to chemotherapy and immunotherapy. Leukemia inhibitory factor (LIF), a member of the interleukin-6 (IL-6) cytokine family, promotes the development and progression of pancreatic cancer and has emerged as a promising therapeutic target. Here, our objectives were to validate the druggability of LIF as a therapeutic target and establish an innovative treatment strategy for pancreatic ductal adenocarcinoma (PDAC) by leveraging antibody-mediated LIF blockade to enhance the efficacy of gemcitabine-based chemotherapy or PD-1-targeted immunotherapy.  \nMethod We generated a humanized anti-LIF antibody using a murine framework as the basis. To minimize immunogenicity, we performed structural optimization of VL/VH domains and employed rational design strategies. Surface plasmon resonance (SPR) was used to determine the binding affinity of the antibody for the LIF antigen. Antitumor efficacy was evaluated across multiple preclinical models, including cancer cell lines, patient-derived organoids (PDOs), cell-derived xenografts（CDXs）, and patient-derived organoid xenografts (PDOXs) . The humanized anti-LIF (h-anti-LIF) antibody was co-administered with either chemotherapy or immunotherapy in these models to assess the impact of the combination on tumor growth.  \nResults The h-anti-LIF antibody demonstrated higher specificity and affinity for LIF compared with its murine counterpart and exhibited superior efficacy in inhibiting tumor growth relative to the murine antibody. Furthermore, our findings revealed that selective targeting of LIF not only enhanced the chemosensitivity of pancreatic cancer to gemcitabine but also improved the efficacy of PD-1-targeted immunotherapy.  \nConclusion Our study demonstrates that the humanized anti-LIF antibody emerges as a promising adjuvant for enhancing the efficacy of both chemotherapy and immunotherapy in pancreatic cancer.  \nKeywords Pancreatic cancer, Leukemia inhibitory factor, LIF, Humanized antibody, Chemotherapy, Immunotherapy  \n*Correspondence:  \nRong Huang [136hr@sina.com](136hr@sina.com)  \nHong Zhao [Zhaohong9@sina.com](Zhaohong9@sina.com)[ ](Zhaohong9@sina.com)Wei Song [songwei@ibms.pumc.edu.cn](songwei@ibms.pumc.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.","cbCaivTCCTvJJTmt","https://ap.wps.com/l/cbCaivTCCTvJJTmt","pdf",3543497,18,"English","# Abstract\n# Introduction\n## Background and clinical challenge\n## Chemotherapy resistance and immunotherapy limits\n## Therapeutic rationale for LIF","[{\"question\":\"What therapeutic target does the study focus on in pancreatic ductal adenocarcinoma?\",\"answer\":\"The study focuses on leukemia inhibitory factor (LIF) and aims to validate LIF as a therapeutic target using antibody-mediated LIF blockade.\"},{\"question\":\"How was the humanized anti-LIF antibody generated and evaluated?\",\"answer\":\"A humanized anti-LIF antibody was created using a murine framework with structural optimization of VL/VH domains to reduce immunogenicity. Binding affinity was measured using surface plasmon resonance (SPR), and antitumor efficacy was tested in multiple preclinical models.\"},{\"question\":\"What outcomes did the study report for combining the antibody with standard treatments?\",\"answer\":\"Selective targeting of LIF enhanced chemosensitivity to gemcitabine and improved the efficacy of PD-1-targeted immunotherapy, with the humanized antibody showing higher specificity, affinity, and tumor growth inhibition than the murine version.\"}]","A humanized LIF-targeting antibody synergistically enhances chemoand immunotherapy in pancreatic cancer | PDF",1790125341,45,[99,103,107,111],{"page_no":22,"url":100,"width":101,"height":102},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78c015a6212bba25694a5b9bdcdfd7c0.webp",983,1310,{"page_no":26,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8537084e76b32a0b3783e950183e8a0.webp",982,1309,{"page_no":30,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f07f24d1a572bf5f39c8571ca56c23f6.webp",981,1308,{"page_no":33,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f8ee5718310528684b3f3e0e2c2e94e.webp",980,1306,{"code":4,"msg":82,"data":116},[117,121,125,129,134,139,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":130,"slug":162},19,"General","general"]